Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Study Pinpoints New Gene for Cystic Fibrosis

Variant can affect disease severity, experts say

By Jeffrey Perkel
HealthDay Reporter


Related Encyclopedia
 border=
Allergic Rhinitis
Allergies
Allergies To Animals In Children
Allergy Immunotherapy
More...

Related Healthscout Videos
 border=
Detecting Lung Disease
Stents for Emphysema
Early Asthma Detection
NEW ALLERGY DROPS
More...

Related Animations
 border=
Allergy
Asthma
More...

Related Drug Information
 border=
Advair Diskus
Allegra
Allegra D
Clarinex
More...

Related News Articles
 border=
Blacks in Nursing Homes Vaccinated Less Than Whites
Exposure to 9/11 Fumes Tied to Chronic Headaches
Health Tip: What's Behind Nasal Congestion
Herbals Not the Answer for Asthma, Study Shows
More...

WEDNESDAY, Feb. 25 (HealthDay News) -- Researchers have identified a new gene associated with cystic fibrosis.

Dr. Christopher Karp, of the Cincinnati Children's Hospital Medical Center, and an international team of colleagues demonstrated that variants in a gene called IFRD1 can modulate the airway disease that marks cystic fibrosis (CF) by muting the pro-inflammatory activities of white blood cells called neutrophils.

Text Continues Below



Crucial in clearing bacterial infections, neutrophils have long been suspects in CF airway disease, Karp said. It was thought that they damage the airway via a hyperactive response to the persistent bacterial infections that plague people with CF.

"I think the significance of the paper is it further strengthens the importance of neutrophil function in modulating disease severity," said Chris Penland, director of research at the Cystic Fibrosis Foundation, which partially funded the study.

Though it's too early to recommend changes in genetic screening or counseling, the findings do implicate IFRD1 in particular, and neutrophil activation in general, as potential targets for drug development.

The results were published online Feb. 25 in Nature.

Researchers have long known that mutations in the gene CFTR were associated with cystic fibrosis, but were unable to account for the spectrum of lung disease severity that accompanies the disease.

That, Karp said, suggested two possibilities: "Either that there are strong environmental influences, and/or there are other genes that modify the expression of lung disease in cystic fibrosis."

A handful of modifiers had already been identified, all related to immune cell function. To identify additional candidates, Karp and his team scanned 100,000 genetic markers, called single nucleotide polymorphisms, across the genomes of two large cohorts of people with CF, looking for markers that segregated with airway disease severity. Of the six genetic variations that emerged, the most promising was IFRD1, which coincidentally is located relatively close to the CFTR gene.

Page:  1 | 2 | 3 | Next >>

Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 2/25/2009

Related Links
 border=
From Healthscout's partner site on asthma, MyAsthmaCentral.com
VIDEO: Lung stents help asthmatics to breathe easier
TREATMENT: Medication and lifestyle changes provide asthma relief
DRUGS: Common drugs used to treat asthma





SOURCES: Christopher Karp, M.D., Gunnar Esiason/Cincinnati Bell chairman and director, Division of Molecular Immunology, and director, Cystic Fibrosis Research Center, Cincinnati Children's Hospital Medical Center, Cincinnati; Chris Penland, Ph.D., director, research, Cystic Fibrosis Foundation, Bethesda, Md.; Robert Giusti, M.D., chief, pediatric pulmonology, and director, Cystic Fibrosis Center, Long Island College Hospital, Brooklyn, N.Y.; Feb. 25, 2009, Nature, online


About The HealthScout Network Contact Us
Copyright © 2001-2010. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy: Updated as of April 1, 2009  Terms of Service   Site Map
Advertising Policy